Using SBRT for reirradiation of ultra-central thoracic tumors
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Peking University Third Hospital · NCT05189054
This study is testing if a special type of radiation therapy called SBRT can safely treat patients with tough-to-reach lung tumors that have come back after previous radiation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05189054 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) for patients with ultra-central thoracic malignant tumors that have previously undergone radiotherapy. The study aims to assess how SBRT can be utilized as a salvage treatment option, particularly for recurrent lung cancer lesions located near critical mediastinal structures. By focusing on high-dose delivery to the tumor while minimizing exposure to surrounding healthy tissues, the study seeks to determine the potential benefits and risks associated with this approach in a challenging clinical scenario.
Who should consider this trial
Good fit: Ideal candidates include patients with a pathological diagnosis of malignant tumors located in the ultra-central chest, who have previously received radiotherapy and have controlled metastasis.
Not a fit: Patients with poor pulmonary function, severe underlying health conditions, or those expected to survive less than three months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with recurrent ultra-central thoracic tumors who have limited alternatives.
How similar studies have performed: Some previous studies have indicated acceptable safety and efficacy of SBRT for similar conditions, but this specific application remains somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological diagnosis is malignant tumor. * The location of the target lesion belongs to the ultra-central type of chest. * The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment. * KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy. Exclusion Criteria: * Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment. * The general condition is poor, and the expected survival time is less than 3 months. * Psychiatric patients or poor compliance, unable to cooperate to complete treatment. * For other reasons, the researcher believes that it is not suitable to participate in this trial.
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Junjie Wang, M.D. — Peking University Third Hospital
- Study coordinator: Zhe Ji, M.D.
- Email: aschoff@163.com
- Phone: 008618710002823
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stereotactic Body Radiation Therapy, Irradiation, Reaction, Thoracic Tumor, Recurrent Cancer